1. Generics Bulletin

English Adalimumab Tender Marks Progress, But Is Not Perfect

 
• By Aidan Fry

An English adalimumab tender in effect from 1 December last year aided industry sustainability by awarding deals to multiple biosimilar suppliers. But there is still room for improvement, the BBA’s Warwick Smith believes.

Tender
Five suppliers each were awarded a portion of the English adalimumab market in a novel model for an NHS tender • Source: Shutterstock

A multisource adalimumab tender run by England’s National Health Service (NHS) on a regional basis late last year was a marked improvement over previous procurement practices for biosimilars, according to Warwick Smith, director general of the British Biosimilars Association (BBA). But it could have been better, he told delegates to Medicines for Europe’s biosimilar medicines conference held in Amsterdam, the Netherlands.

Admitting a degree of surprise at how the industry’s arguments around sustainability had been reflected in the adalimumab tender, Smith stated: “I would not say it is

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.